Inscripta
Inscripta is a biotechnology company that provides scalable digital genome engineering technology, allowing researchers to create low-cost libraries of designer proteins, pathways, or genome variants with precise and trackable mutations.
Inscripta Overview
Inscripta Funding Rounds
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Later Stage | 5/31/2023 | ||||
| Later Stage | 1/18/2023 | ||||
| Series E | 4/5/2021 | ||||
| Series D | 11/30/2020 | ||||
| Series D | 11/11/2019 | ||||
Series C1 | 3/29/2019 |
Inscripta Investors
| Investor | Investment Rounds | Lead Partner | Initial Investment | Other Notable Investments |
|---|---|---|---|---|
| Venrock | Series B, Series C, Series D | Series B (2017-02-16) | ||
| Oak HC/FT | Series D | Series D (2019-11-11) | ||
| D1 Capital Partners | Series E | Series E (2021-04-05) | ||
| Durable Capital Partners | Series E | Series E (2021-04-05) | ||
| GoldenArc | Series E | Series E (2021-04-05) | ||
| T. Rowe Price Group (NAS: TROW) | Series E | Series E (2021-04-05) |
Inscripta 409a Valuations
| Date | Price per share | Est. Valuation | Filling |
|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Inscripta Filings
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
